Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
about
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingA phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
P2860
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@ast
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@en
type
label
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@ast
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@en
prefLabel
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@ast
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@en
P2093
P2860
P1476
Phase I study of enzastaurin a ...... efficacy and pharmacokinetics.
@en
P2093
Connie Collins
Deborah K Armstrong
Donald Thornton
Jeannette Day
Lori Kornberg
Michael A Carducci
Nwabundo Nwankwo
Rodney Decker
Sabine Ermisch
P2860
P2888
P304
P356
10.1007/S10637-012-9850-6
P577
2012-07-06T00:00:00Z